Cargando…
Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy
Neoadjuvant chemotherapy followed by a cystectomy is the standard treatment in muscle-invasive bladder cancer (MIBC). However, the role of chemotherapy in the adjuvant setting remains controversial, and therefore new prognostic and predictive biomarkers are needed to improve the selection of MIBC pa...
Autores principales: | Pardo, Juan Carlos, Sanhueza, Tamara, Ruiz de Porras, Vicenç, Etxaniz, Olatz, Rodriguez, Helena, Martinez-Cardús, Anna, Grande, Enrique, Castellano, Daniel, Climent, Miquel A., Lobato, Tania, Estudillo, Lidia, Jordà, Mireia, Carrato, Cristina, Font, Albert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836680/ https://www.ncbi.nlm.nih.gov/pubmed/35159947 http://dx.doi.org/10.3390/jcm11030497 |
Ejemplares similares
-
Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?
por: Pardo, Juan Carlos, et al.
Publicado: (2020) -
Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2021) -
Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
por: Pardo, Juan C., et al.
Publicado: (2022) -
Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2023) -
Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?
por: Martori, Clara, et al.
Publicado: (2022)